{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:02:03Z","timestamp":1782244923654,"version":"3.54.5"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The neoadjuvant and adjuvant use of immune checkpoint inhibitors (ICIs) in early stage non-small cell lung cancer (NSCLC) is increasing, with pembrolizumab approved as adjuvant therapy following surgical resection and chemotherapy by the U.S. Food and Drug Administration in early 2023. However, clinical trials of these agents have several key limitations including the use of surrogate endpoints that have not been validated and a lack of demonstrated survival benefit. Further data supporting the benefits of ICIs in this setting are necessary to justify their use at the cost of greater financial burdens, time, and adverse effects.<\/jats:p>","DOI":"10.1007\/s00432-023-04749-4","type":"journal-article","created":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T10:02:16Z","timestamp":1683972136000},"page":"9513-9515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC"],"prefix":"10.1007","volume":"149","author":[{"given":"Anushka","family":"Walia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"key":"4749_CR1","doi-asserted-by":"publisher","first-page":"629394","DOI":"10.3389\/fonc.2021.629394","volume":"11","author":"R-L Chen","year":"2021","unstructured":"Chen R-L et al (2021) Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1283 patients. Front Oncol 11:629394","journal-title":"Front Oncol"},{"key":"4749_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344\u20131357","journal-title":"Lancet"},{"key":"4749_CR3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM et al (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386:1973\u20131985","journal-title":"N Engl J Med"},{"key":"4749_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1186\/s12885-022-10046-z","volume":"22","author":"T Hua","year":"2022","unstructured":"Hua T, Gao Y, Zhang R, Wei Y, Chen F (2022) Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. BMC Cancer 22:1022","journal-title":"BMC Cancer"},{"key":"4749_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","volume":"14","author":"A Mauguen","year":"2013","unstructured":"Mauguen A et al (2013) Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data. Lancet Oncol 14:619\u2013626","journal-title":"Lancet Oncol"},{"key":"4749_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M et al (2022) Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 23:1274\u20131286","journal-title":"Lancet Oncol"},{"key":"4749_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","volume":"39","author":"W-Z Zhong","year":"2021","unstructured":"Zhong W-Z et al (2021) Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1\u2013N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. JCO 39:713\u2013722","journal-title":"JCO"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04749-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04749-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04749-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T20:58:06Z","timestamp":1690491486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04749-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4749"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04749-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Disclosure: Vinay Prasad\u2019s Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds\/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack. All other authors have no financial nor non-financial conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}